Kindred Biosciences Lowered to Market Perform at BMO Capital Markets (KIN)
Kindred Biosciences (NYSE:KIN) was downgraded by stock analysts at BMO Capital Markets to a “market perform” rating in a report issued on Wednesday, ARN reports.
Separately, analysts at Guggenheim initiated coverage on shares of Kindred Biosciences in a research note to investors on Monday, January 6th. They set a “buy” rating on the stock.
Kindred Biosciences, Inc is a development-stage biopharmaceutical company. The Company focused on pets.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.